Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNZ-2
- Development stage
- Discontinued
- Lead developer
- Equillium
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
BNZ-2 is a first-in-class, selective inhibitor of the cytokines interleukin-15 (IL-15) and interleukin-21 (IL-21). It is a synthetic peptide therapeutic developed for subcutaneous administration. The drug is designed to address immune-mediated diseases by selectively blocking IL-15 and IL-21, two cytokines that act synergistically in driving the pathology of celiac disease and other inflammatory gastrointestinal and hepatic disorders. By inhibiting these targets, BNZ-2 aims to modulate immune responses implicated in disease progression. The drug has undergone substantial translational work supporting its use as a treatment for various gastrointestinal diseases and is currently being evaluated in Phase 1 clinical trials with proof-of-concept studies planned for patients with celiac disease[5][10].
- Other names
- PEGylated IL-15/IL-21 inhibitor
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL21R (Interleukin-21 receptor)IL15 (Interleukin 15)IL21 (Interleukin-21)
Beyond the preview
Go deeper on BNZ-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNZ-2.